NCT04642404

CBD for Dental Pain

Cannabidiol (CBD) for the Management of Emergency Dental Pain

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: The University of Texas Health Science Center at San Antonio · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaulate CBD as a therapeutic approach for dental pain. Eligible subjects presented with emergency dental pain will be give a single dose of Epidiolex (FDA-approved CBD) or placebo and will be monitored for 3 hours for pain symptoms and psychologic effects.

Detailed description

CBD is a non-psychoactive, non-addictive compound of cannabis that has shown analgesic and anti-inflammatory properties. Epidiolex is the only FDA-approved oral CBD solution and will be the drug of choice in this study.

Conditions

• Odontalgia
• Toothache

Interventions

Type	Name	Description
DRUG	Epidiolex 100 mg/mL Oral Solution	Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain
DRUG	Placebo	Placebo drug will be a solution with the same taste, texture and color as the drug.

Timeline

• Start date: 2021-03-01
• Primary completion: 2023-03-02
• Completion: 2023-03-13
• First posted: 2020-11-24
• Last updated: 2024-05-09
• Results posted: 2024-04-17

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study